

Rabbit anti-Human CES1 Polyclonal Antibody | anti-CES1 antibody

Anti-CES1 Antibody, Rabbit Polyclonal

CATALOG #	HOST	REACTIVITY	APPLICATIONS
AAA256136	Rabbit	Human	Immunoprecipitation, Immunofluorescence, Immunocytochemistry, Immunohistochemistry, Western Blot

PRODUCT SYNONYMS

CES1; Polyclonal Antibody; Anti-CES1 Antibody; Rabbit Polyclonal; CES1 Antibody; Rabbit PAb; Antigen Affinity Purified; carboxylesterase 1; Anti-ACAT Antibody; Anti-CE-1 Antibody; Anti-CEH Antibody; Anti-CES2 Antibody; Anti-hCE-1 Antibody; Anti-HMSE Antibody; Anti-HMSE1 Antibody; Anti-PCE-1 Antibody; Anti-REH Antibody; Anti-SES1 Antibody; Anti-TGH Antibody; anti-CES1 antibody

PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Human
Clonality	Polyclonal
Isotype	Rabbit IgG
Specificity	Human CES1
Purity/Purification	Protein A & Antigen Affinity
Form/Format	Liquid; PBS, pH7.0 with 0.03% Proclin300
Applicable Applications for anti-CES1 antibody	IP (Immunoprecipitation), IF (Immunofluorescence), ICC (Immunocytochemistry), IHC (Immunohistochemistry), WB (Western Blot)
Immunogen	E Coli-derived Human CES1 fragment
Conjugation	Unconjugated
Preparation	Produced in rabbits immunized with E Coli-derived Human CES1 fragment, and purified by antigen affinity chromatography.
Preparation and Storage	This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Avoid repeated freeze-thaw cycles.

IMAGES



IP (Immunoprecipitation)

CES1 was immunoprecipitated using: Lane A: 0.5 mg HepG2 Whole Cell Lysate 4 uL anti-CES1 rabbit polyclonal antibody and 60 ug of Immunomagnetic beads Protein A/G. Primary antibody: Anti-CES1 rabbit polyclonal antibody, at 1:100 dilution. Secondary antibody: Clean-Blot IP Detection Reagent (HRP) at 1:1000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 55 kDa. Observed band size: 60 kDa.



IF (Immunofluorescence)

Immunofluorescence staining of CES1 in HepG2 cells. Cells were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 in PBS, blocked with 10% serum, and incubated with rabbit anti-Human CES1 polyclonal antibody (dilution ratio 1:200) at 4 degree C overnight. Then cells were stained with the Alexa Fluor 488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue). Positive staining was localized to Cytoplasm.



IHC (Immunohistochemistry)

Immunochemical staining of human CES1 in human liver with rabbit polyclonal antibody at 1:100 dilution, formalin-fixed paraffin embedded sections.



WB (Western Blot)

Anti-CES1 rabbit polyclonal antibody at 1:500 dilution Lane A: HepG2 Whole Cell Lysate Lane B: THP1 Whole Cell Lysate Lysates/proteins at 30 ug per lane. Secondary Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution. Developed using the ECL technique. Performed under reducing conditions. Predicted band size: 62 kDa Observed band size: 62 kDa

ADDITIONAL INFORMATION

Related Product Information for anti-CES1 antibody	CES1 encodes carboxylesterase-1, an important drug-metabolizing enzyme with high expression in the liver. Variants generated by the exchange of segments with CES1P1 complicate the genotyping of CES1. CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. However, it has been problematic to express recombinant CES1 in bacterial expression systems due to low solubility, with the CES1 protein being mainly expressed in inclusion bodies, accompanied by insufficient purity issues. CES1 is capable of catalyzing the hydrolysis of a wide range of therapeutic agents, toxins, and endogenous compounds. Accumulating studies have demonstrated associations between the expression and activity of CES1 and the pharmacokinetics and/or pharmacodynamics of CES1 substrate medications.
Product Categories/Family for anti-CES1 antibody	Serine Proteases and Regulators
References	Sanford JC, et al. (2016) Regulatory effects of genomic translocations at the human carboxylesterase-1 (ces1) gene locus. Pharmacogenet Genomics 26 (5): 197-207. Rasmussen HB, et al. (2015) Individualization of treatments with drugs metabolized by ces1: Combining genetics and metabolomics. Pharmacogenomics 16 (6): 649-665. Qian Y, et al. (2020) Natural products as modulators of ces1 activity. Drug Metab Dispos 48 (10): 993-1007. Ferrero-Miliani L, et al. (2017) Reappraisal of the genetic diversity and pharmacogenetic assessment of ces1. Pharmacogenomics 18 (13): 1241-1257.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/polyclonal/ces1-antibody-immunoprecipitation-immunofluorescence-immunocytochemistry-immunohistochemistry-western-blot-elisa/256136>